Studies demonstrate BEXXAR's efficacy against indolent lymphomas
The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (tositumomab and iodine I-131 tositumomab) therapy regimen for patients with rituximab-refractory indolent lymphomas.
The first Phase II study looked at 76 patients with previously untreated stage III or stage IV follicular lymphoma and, following a single course of treatment with Bexxar, demonstrated a 10-year overall survival rate of 83% and a 10-year progression-free survival rate of 38%.
"We are seeing a consistent result and effect on survival by treating patients with BEXXAR first," said lead investigator Mark Kaminski, MD, Professor of Internal Medicine and Director, the University of Michigan Leukemia/Lymphoma Program. "Rarely are there data to show a treatment can produce a durable response over a decade, and what's most exciting is that these results were achieved after a single treatment."
Another Phase II study looked at 40 patients with either follicular lymphoma or transformed B-cell lymphoma whose disease was proving to be rituximab-refractory after at least one course of rituximab treatment. All patients received a therapeutic dose of BEXXAR.
"Of the patients who had a response to treatment, 39% were in continued response at five years, including five of the nine complete responders," said Sandra Horning, MD, of the Eastern Cooperative Cancer Group and Stanford University. "These data demonstrate durable response rates of tositumomab and Iodine-131 tositumomab in an indolent lymphoma population with disease progression after rituximab."
Call 1-877-399-5078 Anytime To Discuss Treatment Options
If you or a loved one has been diagnosed with Lymphoma, please call toll-free 1-877-399-5078 for treatment options.
The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
More Information
SupportGroups.com
SupportGroups.com is for individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Improved diagnosis has contributed greatly to the increase as doctors better understand cancer of lymphocytes and can distinguish it from other diseases.
